Eclipsebio has acquired Eclipsebio for an undisclosed amount, a strategic move announced today that consolidates the company's pioneering efforts in RNA technology.
The acquiring entity, Eclipsebio, is widely recognized for its development of first-in-class technologies, advanced analyses, and comprehensive platforms essential for the progression of tomorrow’s RNA-based and RNA-targeting therapies. With extensive experience spanning early-stage basic research to preclinical vaccine and gene therapy evaluation, Eclipsebio provides unparalleled support for obtaining deep insights into RNA and therapeutic biology. The acquired entity, also named Eclipsebio, similarly offers these solutions through end-to-end partnerships, including custom assay development, for biopharma and biotech companies, alongside a la carte services.
This strategic acquisition is anticipated to significantly strengthen and streamline Eclipsebio's core operations and offerings. The consolidation is expected to enhance the optimization and characterization of RNA-based vaccines and therapeutics via its eMERGE platform. Furthermore, synergies will deepen the multiomic characterization of small molecule and small oligonucleotide targets, ensuring robust validation of on-target effects and precise identification of off-target effects from various drugs. The integration is also set to bolster deep profiling of RNA, fostering groundbreaking discoveries in academic research and expanding the company's capacity to provide critical insights for RNA success.
Operating as a unified entity, the combined Eclipsebio is poised to reinforce its market leadership and accelerate innovation in the rapidly evolving field of RNA therapeutics. This strategic alignment aims to deliver enhanced value and expanded capabilities to its partners and the broader scientific community.